iiinova — where your digital self keeps evolving

Christoffer Merrild @c-merrild.bsky.social · 16/09/2026

Enormously grateful to my PI, @clemmensenc.bsky.social, Jonas Odgaard Petersen, and the whole team across the Clemmensen, @adeshmukh.bsky.social and @tunepers.bsky.social at @cbmr.science and Fritzen Group at BMI - this was a true collaborative effort and I couldn't be more thankful.

020

Christoffer Merrild @c-merrild.bsky.social · 16/09/2026

Result: synergistic, dose-dependent weight loss beyond either drug alone, better metabolic markers, and some experimental doses supports suppression in food intake without causing aversion.

120

Christoffer Merrild @c-merrild.bsky.social · 16/09/2026

It's out now in Nature Metabolism 💉 Most obesity meds hit 1-2 hormone receptors (GLP-1R ± GIPR), and they're quite effective, but doses a being pushed to achieve greater weight loss = more side effects. We combined retatrutide (GLP-1R/GIPR/GCGR) with cagrilintide (AMLNR/CALCR) in obese rats.

nature.com

Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats - Nature Metabolism

Combination therapy with retatrutide and cagrilintide lowers body weight and improves markers of metabolic health in obese, male rats more efficiently than equimolar monotherapies and matched-dose com...

252

Christoffer Merrild @c-merrild.bsky.social · 07/04/2026

In our new paper in the special issue at @jphysiol.bsky.social, we show that FGF21-glucagon signalling drives sex-specific effects on weight loss and glucose tolerance in obese mice, and uncover an unexpected FGF21-deficiency-driven susceptibility to obesity in females.

131